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Background. We sought to quantify the survival beneﬁts attributable to antiretroviral therapy (ART) in South
Africa since 2004.
Methods. We used the Cost-Effectiveness of Preventing AIDS Complications–International model (CEPAC) to
simulate 8 cohorts of human immunodeﬁciency virus (HIV)–infected patients initiating ART each year during
2004–2011. Model inputs included cohort-speciﬁc mean CD4
+ T-cell count at ART initiation (112–178 cells/µL),
24-week ART suppressive efﬁcacy (78%), second-line ART availability (2.4% of ART recipients), and cohort-speciﬁc
36-month retention rate (55%–71%). CEPAC simulated survival twice for each cohort, once with and once without
ART. The sum of the products of per capita survival differences and the total numbers of persons initiating ART for
each cohort yielded the total survival beneﬁts.
Results. Lifetime per capita survival beneﬁts ranged from 9.3 to 10.2 life-years across the 8 cohorts. Total esti-
mated population lifetime survival beneﬁt for all persons starting ART during 2004–2011 was 21.7 million life-
years, of which 2.8 million life-years (12.7%) had been realized by December 2012. By 2030, beneﬁts reached 17.9
million life-years under current policies, 21.7 million life-years with universal second-line ART, 23.3 million life-
years with increased linkage to care of eligible untreated patients, and 28.0 million life-years with both linkage to
care and universal second-line ART.
Conclusions. We found dramatic past and potential future survival beneﬁts attributable to ART, justifying inter-
national support of ART rollout in South Africa.
Keywords. HIV; South Africa; highly active antiretroviral therapy.
South Africa’s human immunodeﬁciency virus (HIV)
epidemic is the largest in the world, with 5.6 million
HIV-infected persons in 2011, as estimated by the Joint
United Nations Programme on HIV/AIDS (UNAIDS)
[1]. Of these, roughly 2.6 million met antiretroviral
therapy (ART) eligibility criteria in 2012. This number
in part reﬂects the expansion of eligibility criteria from
a CD4
+ T-cell count of <200 cells/µL or World Health
Organization (WHO) stage 4 illness in 2004 [2]t o
include patients with multidrug-resistant (MDR) tu-
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+
T-cell count of<350 cells/µL in 2010 [3]. Yet, despite impres-
sive commitments to expand access to ART [4], one-third
(800 000) of these eligible individuals remained without treat-
ment. Meanwhile, current economic challenges have
prompted resource-allocation debates that might jeopardize the
ongoing treatment of individuals who are already receiving
ART and the linkage to care of untreated patients who are eligi-
ble for treatment.
We sought to invigorate discussions of prioritizations for
HIV care by quantifying both the cumulative survival beneﬁts
of ART since its introduction in South Africa in 2004 [5] and
the additional returns that could be obtained via expanded
rollout investments. Previous studies provide indirect evidence
of the survival beneﬁts conferred by ART in sub-Saharan
Africa. During 2001–2011, the estimated number of HIV-in-
fected persons living in sub-Saharan Africa steadily increased
from 20.9 million to 23.5 million; during this time horizon,
owing to the roll out of ART, annual HIV-related deaths de-
creased by 600000 (32%) during 2005–2011 [6]. In African
countries focused on by the US President’s Emergency Plan for
AIDS Relief (PEPFAR), national mortality rates [7] were lower
during 2004–2008 compared with nonfocus countries [8].
Comparison of adult life expectancy before and after ART roll-
out in rural KwaZulu Natal revealed an 11.3-year increase [9].
However, to our knowledge, no prior studies have quantiﬁed
the direct impact of ART rollout on population survival. The
objective of our study was to use computer simulation to quan-
tify this impact in South Africa and, byextension, to extrapolate
the future survival beneﬁts of further ART rollout.
METHODS
Analytic Overview
Survival beneﬁts attributable to ART in South Africa were esti-
mated using the Cost-Effectiveness of Preventing AIDS Com-
plications–International model of HIV disease and treatment
(CEPAC) [10–13]. We deﬁned 8 independent cohorts repre-
senting adult (age, >14 years) HIV-infected persons initiating
ART in a given year during 2004–2011. The size of each cohort
was derived from UNAIDS reports [1]. These included only
persons who initiated therapy in that year. As the simulation
progressed, each of these cohorts experienced attrition through
mortality and loss to follow-up. No new patients were added to
the cohorts after simulation start.
CEPAC simulated the experience of individual HIV-
infectedpersons;theresultsofmanyindividualsimulationswere
aggregated to project population-level outcomes. Two simula-
tions were run for each cohort; in one simulation all members
initiated ART, and in the other no members initiated ART.
Comparison of cohort survival between the ART and no-ART
simulations yielded cohort-speciﬁc per capita survival beneﬁts
attributable to ART. The initial size of each cohort was calculat-
ed using published reports of numbers of persons receiving
ARTeach year [1]and ART program retention (Supplementary
Materials)[ 14, 15]. Total survival beneﬁts were calculated by
adding the products of per capita survival beneﬁts and initial
size of each treated cohort. Beneﬁts were distinguished between
those already realized (censored as of December 2012) versus
those yet to be realized (censored as of December 2030 and un-
censored), given conservative assumptions of no new patients
initiating ART after 2011 and no improvements in HIV-related
care or ARTefﬁcacy.
Model Overview
CEPAC is a state-transition microsimulation model of HIV
disease [10–13]. CEPAC simulates each HIV-infected person’s
lifetime as a series of monthly transitions between health states
representing asymptomatic HIV infection, symptomatic HIV
infection, and death. Health states are designed to predict
disease progression, as reﬂected by probabilities of transition to
other states. Health states are stratiﬁed by prognostic indicators,
including HIV disease history (eg, past opportunistic disease),
CD4
+ T-cell count, and HIV RNA level. HIV RNA level drives
the rate of CD4
+ T-cell count decline in the absence of treat-
ment [16]. CD4
+ T-cell count, in turn, determines the monthly
probabilities of developing an opportunistic disease or dying.
The monthly risk of HIV-related mortality is generally higher
for symptomatic states than for asymptomatic states [17].There
is also a monthly age- and sex-stratiﬁed risk of non–HIV-
related death for all individuals [18].
The efﬁcacy of trimethoprim-sulfamethoxazole prophylaxis
(which is assumed available to all patients [19])is modeled as a
reduction in the CD4
+ T-cell count–dependent risk of opportu-
nistic disease (including bacterial diseases, toxoplasmosis, and
pneumocystosis). ART efﬁcacy is modeled as a reduction in
HIV RNA level with a concomitant increase in CD4
+ T-cell
count, as well as a resultant decrease in the probabilities of
HIV-related death and all opportunistic diseases. In accordance
with WHO guidelines, ﬁrst-line ART failure is deﬁned as the
development of a WHO stage 3 or 4 opportunistic disease or a
CD4
+ T-cell count decrease below either the pre-ART nadir,
100 cells/µL absolute value, or 50% of the peak value [20].
Treatment for patients experiencing ﬁrst-line therapy failure
(deﬁned, in the assumed absence of HIV RNA load monitor-
ing, as onset of an opportunistic disease or achievement of
CD4
+ T-cell count failure criteria) entailed transition to
second-line ART, if available. To reﬂect treatment resource lim-
itations, the availability of second-line ART for simulated
persons in whom ﬁrst-line therapy failed was limited to the
percentage of all ART recipients (2.4%, as reported by the
WHO [21]) who were receiving second-line therapy (including
those in whom ﬁrst-line therapy did not fail) in low- and
middle-income countries outside of the Americas.
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patients without ART for each cohort to achieve stable per
capita survival beneﬁt estimates. Comparison of per capita sur-
vival between the simulations with and those without ART
yielded cohort-speciﬁc per capita survival beneﬁt estimates.
The sum of the products of CEPAC-generated per capita sur-
vival beneﬁts and numbers of persons initiating ART for each
cohort (see cohort size estimates, below) yielded the total
number of life-years attributable to ART initiated during 2004–
2011 (Supplementary Materials).
Model Inputs
We used data from the Southern African Catholic Bishops
Conference cohort to estimate mean age ± SD (37 ± 10 years),
sex distribution (33% male), HIV RNA level distributions (46%
with an HIV RNA level of>100 000 copies/mL), and mean
CD4
+ T-cell count at ART initiation (112–178 cells/µL during
2004–2011) of the simulated cohorts [22, 23]. HIV disease
natural history parameters, including chronic AIDS mortality
and opportunistic disease incidence and mortality, were taken
from the Cape Town AIDS Cohort [17]. Non-HIV mortality
was estimated using United Nations life tables for South Africa,
with adjustment to remove HIV-related mortality [18].
Longitudinal cohort analysis yielded the effect of ART (inde-
pendent of CD4
+ T-cell count rise) on additional reductions in
chronic AIDS mortality (56%–96%) and opportunistic disease
incidence (32%) [24]. Derived ART efﬁcacy parameters includ-
ed a 6-month HIV RNA suppression probability of 78% [25], a
mean CD4
+ T-cell count increase 6 months after ART initia-
tion of 148 cells/µL [26], and a 0.8% monthly probability of
virologic rebound after 6 months for those in whom the HIV
RNA level was initially suppressed (Table 1)[ 25].
Cohort Size Estimates
We estimated the number of persons initiating ART each year
(ie, the initial size of each cohort), using data from the Joint
United Nations Programme on HIV/AIDS (UNAIDS) [1].
These data describe the number of persons receiving ART each
year but do not specify when they initiated ART. We therefore
calculated the difference between the UNAIDS-reported total
number of persons receiving ART during December of a given
year and the total receiving ART during December of the previ-
ous year. This latter number was adjusted downward to reﬂect
attrition due to both loss to follow-up and mortality [14,15,27,
28]. In the case of the ﬁrst cohort, which initiated therapy in
2004, the UNAIDS-reported value was assumed to represent
exactly the number of persons initiating ART during that year,
because there were no data from earlier reported cohorts to
subtract.
Annual cohort attrition comprised losses due to both mor-
tality and loss-to-follow-up as reported by meta-analyses:
18.5%–27.6% during the ﬁrst year, 8.3%–19.8% during the
second year, 5.4%–5.8% during the third year, and 2.6%–2.8%
thereafter (Supplementary Table 1)[ 14,15, 27, 28]. These base-
case retention loss estimates exceed those reported by various
South African cohorts with 5–6 years of follow-up data [29,
Table 1. Model Parameter Inputs
Model Parameter
Base-Case
Value
Range
Examined
Cohort characteristic
a
Age, y, mean ± SD [22,23] 3 7±1 0 ...
Male sex, subjects, % [22, 23] 3 3 ...
CD4
+ T-cell at ART initiation, cells/μL, mean ± SD [22, 23]
2004 112± 95 38–157
2005 127± 124 38–172
2006 133± 133 46–178
2007 145± 143 51–189
2008 149± 132 52–197
2009 156± 147 56–197
2010 178± 345 70–232
2011 173± 144 73–230
Initial HIV RNA level, patients, % [22, 23]
>100000 copies/mL 46 . . .
30001–100000 copies/mL 33 . . .
10001–30000 copies/mL 21 . . .
<10001 copies/mL 0 . . .
Disease natural history
Monthly risk of AIDS-attributable death without ART, patients, %,
by CD4
+ T-cell count
b [17]
0–50 cells/μL4 –1 0 ...
51–100 cells/μL2 –5 ...
101–200 cells/μL1 –3 ...
201–350 cells/μL
c 0 ...
351–500 cells/μL
c 0 ...
>500 cells/μL
c 0 ...
Antiretroviral therapy
ARTefficacy, 2 lines (NNRTI+2 NRTIs and PI+2 recycled NRTIs)
b
HIV RNA suppression at 6 mo,
patients, % [25]
78 54–97
CD4
+ T-cell count increase at
6 mo, cells/μL, mean [26]
148 102–225
Monthly risk of ART failure after
6 mo once suppressed, % [25]
0.8 0.4–0.9
Second-line ART availability, all
patients receiving ART, % [21]
2.4 0–4.8
ART program retention at 12 mo,
patients, %
d [14,15, 27, 28]
72.4–81.5 63.8–81.5
Abbreviations: NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI,
nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor
a Model inputs were derived from additional analysis of the primary dataset on
which the cited papers reported.
b Ranges reflect distributions of base-case inputs, based on each person’s
history of opportunistic disease.
c Input values are nonzero but are reported as zero because of rounding.
d Ranges reflect value differences in retention for each of the 8 cohorts (see
Methods).
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assigned to start in each cohort were calculated such that the
number of persons alive across all cohorts summed to
UNAIDS-reported numbers of persons receiving ART in South
Africa each year [1]. In this way, we ensured that the model
cohort sizes never exceeded the numbers of persons reported to
be receiving ART by UNAIDS data. After the eighth cohort ini-
tiated treatment, in 2011, no additional persons were added to
the analysis (Supplementary Materials). Once patients were lost
to follow-up, they were assumed to never re-enter care to make
our survival gain estimates more conservative.
Sensitivity Analyses
We conducted sensitivity analyses to examine the impact of
uncertainty in base-case parameter input values (Table 1) and
assumptions on projected survival beneﬁts. These analyses in-
cluded alternative inputs reﬂecting uncertainty in numbers of
persons initiating ART each year [1], mean CD4
+ T-cell count
upon ART initiation [22,23],CD4
+ T-cell count and HIV RNA
level monitoring availability [20, 31, 32], ART efﬁcacy [26, 33–
37], second-line ART availability [21], and ART program
retention (Supplementary Materials)[ 14, 15]. We also simul-
taneously changed all of these variables to generate best- and
worst-case scenarios reﬂecting uncertainty in all base-case
inputs.
Additional Analyses
Additional analyses examined outcomes through 2030 for sce-
narios in which prospective policy decisions accelerate the roll
out of HIV treatment services as of January 2014. These
scenarios included universal access to second-line ART (rather
than the base-case 2.4% availability) and future annual linkage
to care of eligible HIV-infected persons not yet receiving ART.
The latter scenarios assumed that 34% of eligible patients were
not yet receiving ART [1], that the HIV-infected population
size grew according to the projections by the Actuarial Society
of South Africa [38],and that 10% of untreated eligible patients
were linked to care each year. Maximum potential beneﬁts
from increased linkage to care were projected by examining
alternative annual rates of linkage to care up to 84% [39].
RESULTS
Survival Beneﬁts
The number of persons initiating ART each year grew from
50 100 in 2004 to 557300 in 2011. In total, 2222700 individuals
were estimated to have initiated ART during 2004–2011. Regard-
ing censored survival beneﬁts, the cohort initiating ART in 2004
had an estimated per capita life expectancy of 1.9 years in the
simulation without ART, compared with 5.9 years in the simula-
tion with ART, fora percapita increase of 4.0 life-years. Censored
per capita survival beneﬁts decreased for subsequent cohorts,
with a low of 0.2 life-years for the cohort initiating ART in 2011.
The sum of products of the numbers of patients newly initiating
ARTand the censored percapita survival beneﬁts yielded an esti-
mated 2.8 million life-years as of December 2012 (Table 2).
Regarding lifetime (uncensored) survival beneﬁts, the cohort
initiatingARTin2004hadanestimatedpercapitalifeexpectancy
of 1.9 years in the simulation without ART, compared with
11.2 years in the simulation with ART, for a per capita increase
Table 2. Survival Beneﬁts Attributable to Antiretroviral Therapy (ART) in South Africa
Cohort
Year of
ART
Initiation
A:
Persons
Initiating
ART, No.
a
Censored at December 2012, Life-Years Not Censored (Lifetime Benefits), Life-Years
B: Per Capita
Life
Expectancy,
Simulation
With ART
C: Per Capita
Life
Expectancy,
Simulation
Without ART
D: Per Capita
Survival
Benefit,
2004–2012
b
[B – C]
E: Survival
Benefit,
2004–
2012
[A×D]
B′: Per Capita
Life
Expectancy,
Simulation
With ART
C′: Per Capita
Life
Expectancy,
Simulation
Without ART
D′:P e r
Capita
Survival
Benefit,
Lifetime
[B′ – C′]
E′: Survival
Benefit,
Lifetime
[A×D′]
2004 50100 5.9 1.9 4.0 199300 11.2 1.9 9.3 463800
2005 152100 5.5 2.1 3.4 518700 11.5 2.1 9.4 1429100
2006 154700 5.0 2.2 2.8 442200 11.7 2.2 9.5 1469300
2007 182600 4.4 2.2 2.2 396900 11.6 2.3 9.3 1694300
2008 314900 3.8 2.2 1.6 522600 12.1 2.3 9.8 3082700
2009 319000 3.1 2.0 1.1 333500 12.3 2.4 9.9 3152300
2010 491900 2.3 1.8 0.5 240400 13.0 3.3 9.7 4768900
2011 557300 1.4 1.2 0.2 99 300 12.7 2.5 10.2 5671000
Total 2222700 2752800 21731300
a Calculated using reports of numbers of persons receiving ARTeach year [1] and ART program retention losses [14, 15].
b Calculated by subtracting life expectancies during 2004–2012 for the no-ART simulations (column C) from those for the ART simulations (column B). Survival
gains in 2004 are thus measured over 9 years, whereas those in 2011 are measured over 2 years.
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cohorts were comparable, ranging from 9.3 to 10.2 life-years.
The sum of products of the numbers of patients newly initiat-
ing ART and the lifetime per capita survival beneﬁts yielded an
estimated 21.7 million life-years (Table 2). Of this expected
total, 18.9 million life-years (87.3%) had yet to be attained.
Univariate Sensitivity Analyses
Univariate sensitivity analyses demonstrated that the base-case
lifetime survival beneﬁt estimate (21.7 million life-years) was
most sensitive to uncertainty regarding ART efﬁcacy (probabil-
ity of initial viral suppression, CD4
+ T-cell count rise, and
probability of late ART failure), yielding lifetime survival bene-
ﬁts ranging from 14.0 to 35.4 million life-years. Lifetime surviv-
al beneﬁts were also sensitive to ART program retention
(17.4–23.0 million life-years) and numbers of persons receiving
ART (19.7–23.7 million life-years). Lifetime survival beneﬁts
were comparatively insensitive to the WHO monitoring guide-
lines followed for guiding the transition to second-line ART,
uncertainty in the availability of second-line ART, and CD4
+
T-cell count at ART initiation (Figure 1).
Best- and Worst-Case Scenarios
All ranges of values used in the univariate analyses were used si-
multaneously in a multivariable analysis to establish worst- and
best-case scenarios reﬂecting uncertainty in all variables listed in
Figure 1. In the worst-case scenario, lifetime survival beneﬁts
reached 10.2 million life-years, of which 2.2 million life-years
(21.8%) had already been realized as of December 2012. The best-
case scenario resulted in lifetime survival beneﬁts of 37.6 million
life-years, of which 3.0 million (8.1%) had already been realized.
Prospective Policy Analyses Projections to 2030
Additional analyses examined hypothetical scenarios of
implementing various policy initiatives associated with HIV
treatment and linkage to care in January 2014, projected to De-
cember 2030 (Figure 2). The base-case survival beneﬁts were
projectedto reach17.9 million life-years. Ascenario ofuniversal
access to second-line ART starting in January 2014 increased
these beneﬁts to 21.7 million life-years. Implementation of
annual linkage to care of 10% of eligible untreated HIV-
infected patients yielded 23.3 million life-years. Finally, univer-
sal access to second-line ART coupled with expanded case
detection yielded 28.0 million life-years.
Maximum Potential Beneﬁts
Additional analyses demonstrated the sensitivity of these future
projections through December 2030 to the annual proportion of
untreated HIV-infected persons assumed to be linked to care
each year with expanded testing (Figure 3). Survival beneﬁts
plateau with increasing linkage-to-care rates; at higher rates
nearly all eligible patients are ultimately linked to care and so ad-
ditional rate increases do not increase numbers of patients ulti-
mately receiving ART but rather only achieve earlier ART
initiation. In a scenario of increased linkage to care only and
base-case availability of second-line ART for no more than 2.4%
Figure 1. Results of univariate sensitivity analyses. The analyses examined the impact of adjusting selected model parameter values (individual bar
labels) on the basis of cumulative survival beneﬁts attributable to antiretroviral therapy (ART) in South Africa, in life-years (horizontal axis). The ranges of
input values for each parameter are indicated alongside the corresponding bar graph. Results were most sensitive to ART efﬁcacy, ART program retention,
and the numbers of persons initiating ART. Abbreviation: HIV, human immunodeﬁciency virus.
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reached 25.9 million life-years with 20% linkage to care and up
to 29.4 million life-years with 84% linkage to care. In a scenario
of universal access to second-line ART starting in 2014, survival
beneﬁts as of 2030 reached 31.2 million life-years with 20%
linkage to care and up to 35.6 million life-years with 84% linkage
to care.
DISCUSSION
We provide a model-based estimate of the survival beneﬁts at-
tributable to ART in South Africa. In the base case, 21.7
million life-years were attributable to ART over the lifetime of
all persons initiating ART during 2004–2011, of which only 2.8
million life-years (12.7%) had been realized as of December
2012. Implementation of expanded testing and treatment poli-
cies starting in 2014 were projected to signiﬁcantly increase
these beneﬁts. By 2030, survival beneﬁts will reach 17.9 million
life-years under current policies, assuming no new patients ini-
tiate ART. This is only 82% of the potential beneﬁts with uni-
versal second-line ART access (21.7 million life-years), 77% of
the beneﬁts with annual linkage to care of 10% of untreated
eligible patients (23.3 million life-years), and 50% of the poten-
tial beneﬁts with annual linkage to care of 84% of untreated eli-
gible patients and universal second-line ART access (35.6
million life-years).
This study contributes to a growing literature establishing
the profound survival beneﬁts resulting from investments in
the global response to the HIV pandemic [8, 40, 41]. Approxi-
mately $13.7 billion was invested in 2008 alone, including 31%
from direct bilateral funding (namely PEPFAR), 12% from
multilateral institutions (including the Global Fund), and 5%
from philanthropic sources, such as the Bill and Melinda Gates
Foundation [27,42]. These investments have already saved mil-
lions of life-years, but this analysis highlights that little more
than one-tenth of the survival beneﬁts made possible by
current policies have been realized in South Africa. Further-
more, these beneﬁts may be substantially increased through
more-aggressive linkage to care of untreated eligible HIV-
infected patients and expansion of access to second-line ART.
Realizing the full potential return on investments already made
will require that funding sources remain committed to main-
taining and expanding resources available for monitoring, re-
tention, and treatment.
Figure 2. Survival beneﬁts in South Africa following implementation of expanded human immunodeﬁciency virus (HIV) treatment and linkage-to-care
policies, 2004–2030. Projections assume an annual HIV-infected population size projected by the Actuarial Society of South Africa [38]. The projections
are depicted as cumulative survival beneﬁts in millions of life-years (vertical axis), as a function of calendar year (horizontal axis). The vertical line demar-
cates January 2014, the time at which increased linkage to care and treatment is assumed to begin. Base-case survival beneﬁts reached 17.9 million
life-years by December 2030 (solid gray line). Universal access to second-line antiretroviral therapy (ART) starting in January 2014 yielded 21.7 million life-
years (dashed grey line). Linkage to care of 10% of eligible untreated HIV-infected patients each year yielded 23.3 million life-years by 2030 (solid black
line). Finally, universal access to second-line ART coupled with expanded case detection yielded 28.0 million life-years by 2030 (dashed black line).
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sources of uncertainty in quantifying population survival gains
attributable to ART during 2004–2011. However, because sur-
vival gains are calculated as the difference in survival between a
cohort receiving ART and an identical cohort not receiving
ART, sensitivity analyses of parameters informing population
characteristics (eg, CD4
+ T-cell count) are not comparisons of
alternative ART initiation policies. Instead, these results repre-
sent a measure of the impact on survival gain estimates of the
uncertainty in the mean CD4
+ T-cell counts of all HIV-
infected patients initiating ART in South Africa during 2004–
2011. Indeed, while cohort data from sub-Saharan Africa
demonstrate that ART initiation at higher CD4
+ T-cell counts
results in increased survival [43], our results demonstrate the
relative insensitivity of survival gains to the cohort mean CD4
+
T-cell count. The limited impact of CD4
+ T-cell count at ART
initiation reﬂects a counterbalancing of increased survival in
the treatment scenario by increased survival in the counterfac-
tual scenario without ART.
The results of this study reﬂect an intentionally conservative
estimate of survival beneﬁts attributable to ART in South
Africa. The base-case scenario assumed that no additional
persons enrolled in ART beyond those already being treated as
of the end of 2010, that no improvement in ART efﬁcacy
occurred, and that second-line ART availability was limited to
2.4% of all persons being treated with ART. The analyses of
more-frequent testing and more-comprehensive treatment pol-
icies demonstrate dramatic increases in survival beneﬁts when
these unfavorable assumptions are relaxed, with the potential
to more than double the survival beneﬁts under current policies
by 2030 in the most-expanded linkage to care and treatment
scenarios.
Our analysis demonstrates substantial survival beneﬁts in a
scenario of future increased linkage to care of untreated HIV-
infected persons eligible for ART but not yet receiving treat-
ment [44]. Indeed, the UNAIDS estimates that one-third of
HIV-infected persons living in South Africa who are eligible for
ART are not yet receiving treatment [1],posing an opportunity
to expand access to life-extending medication [11,45].Such ex-
pansion will require 2 components. First, expanded case detec-
tion through HIV testing will be necessary; national surveys
suggest that half of South Africans have never been tested for
HIV [46]. Second, as case detection increases, larger numbers
of HIV-infected persons will be identiﬁed before they are eligi-
ble for ART, and so it will become increasingly important to
track and monitor these persons until they are eligible for ART.
Furthermore, our sensitivity analyses illustrate that the rate at
which untreated eligible patients are linked to care drives sur-
vival beneﬁts, demonstrating the impact of speed of scale-up on
survival [13]. Base-case survival beneﬁts as of 2030 range from
17.9 million life-years without linkage to care of any additional
patients to 29.4 million life-years with immediate linkage to
care of 84% of untreated patients eligible for ARTeach year.
This analysis has several limitations. First, the total survival
beneﬁt estimates relied on the accuracy of UNAIDS data on the
numbers of persons receiving ART each year [1]. Second, the
model does not capture the beneﬁts of preventing secondary
transmission. Third, our analysis considers only adults, neglect-
ing survival beneﬁts attributable to prevention of mother-to-child
transmission [47] and treatment of HIV-infected children [48].
Finally, our future survival gain projections to 2030 and beyond
relyonmanyassumptions,includingpredictableepidemicgrowth,
stable health and demographic characteristics of ART recipients,
consistent HIV treatment policy and ART program performance,
reliable treatment-funding sources, and stable treatment efﬁcacy.
To the extent that any of these assumptions do not reﬂect reality,
our projections regarding the future beneﬁt of ART and ART
policy changes would differ accordingly.
Since emerging as the epicenter of the HIV pandemic in the
early 1980s, South Africa has endured devastating losses, with
AIDS-related deaths exceeding 200000 persons each year since
2001 [1]. These deaths have undermined families, societies, and
economies throughout the country. This analysis highlights the
dramatic capacity for HIV treatment to stem this tide of disease
in South Africa, projecting 2.8 million years of life already
gained. That said, this analysis ﬁnds that the lifetime survival
Figure 3. Sensitivity analyses of survival beneﬁt projections following
expanded human immunodeﬁciency virus (HIV) treatment and linkage-
to-care policies in South Africa. Survival beneﬁts are reported in millions of
life-years as of December 2030 (vertical axis). Sensitivity analyses exam-
ined alternative values for the annual proportion of untreated HIV-infected
persons eligible for antiretroviral therapy (ART) who are linked to care
each year as a result of expanded testing (horizontal axis). In a scenario of
increased linkage to care only and base-case availability of second-line
ART for no more than 2.4% of ART recipients at any given time, survival
beneﬁts as of 2030 reached 25.9 million life-years with 20% linkage to
care and 29.4 million life-years with 84% linkage to care (solid line). In a
scenario of universal access to second-line ART starting in 2014, survival
beneﬁts as of 2030 reached 31.2 million life-years with 20% linkage to
care and 35.6 million life-years with 84% linkage to care (dashed line).
Survival Beneﬁts of ART in South Africa ￿ JID 2014:209 (15 February) ￿ 497beneﬁts attributable to ART in South Africa by 2030 range
from 17.9 million life-years under current treatment policies up
to 35.6 million with a combination of aggressive linkage to care
and unrestricted second-line ART availability. Realization of
these future potential beneﬁts will require not only drugs but
also commitment by the international community to continue
implementing and reﬁning effective treatment programs and
practices.
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